ArticlePLoS pathogens2026
A designed peptide disrupting viral protease cleavage restores cGAS-DNA phase separation and type I interferon responses.
Article in PLoS pathogens, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Seneca Valley Virus (SVV) 3C protease is essential for viral polyprotein processing and virion assembly. Meanwhile, it has evolved to cleave and antagonize the multiple innate immune proteins, enabling viral immune evasion. Inhibitors of 3C protease are therefore powerful antiviral agents. Among these, antiviral peptide inhibitors hold particular promise because of their high specificity, strong efficacy, and broad-spectrum activity, and minimal side effects. Here, we developed a dimerization-dependent red fluorescent protein (ddRFP) biosensor system to screen anti-SVV 3C peptides and identified a substrate-competitive decapeptide (P5) that markedly suppresses 3C protease activity. P5 inhibited 3C-mediated cleavage of multiple key immune proteins, including porcine cGAS (pcGAS), porcine Gasdermin A (pGSDMA) and porcine Pro-IL-1β (sPro-IL-1β). Mechanistically, P5 directly interacted with the catalytic His48 site of 3C protease through hydrogen bonding. Remarkably, P5 restored the formation of cGAS-DNA liquid-liquid phase separation (LLPS) by competitively blocking 3C cleavage activity, thereby enhancing cGAS activity and downstream antiviral interferon signaling. Furthermore, P5 demonstrated favorable cellular permeability, low cytotoxicity, good stability and robust antiviral activity. Our findings establish P5 as a highly promising peptide inhibitor of SVV 3C protease with strong translational potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.